Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Feb;29(2):263-5.
doi: 10.1002/mds.25734. Epub 2013 Dec 3.

Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial

Radu Constantinescu  1 , Jordan Elm, Peggy Auinger, Saloni Sharma, Erika F Augustine, Laith Khadim, Karl Kieburtz; NET-PD Investigators
Affiliations
Clinical Trial

Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial

Radu Constantinescu et al. Mov Disord. 2014 Feb.

Abstract

Background: The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.

Methods: Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years.

Results: A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6).

Conclusions: The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.

Keywords: Parkinson's disease; clinical trial; malignant melanoma; standardized event ratio.

PubMed Disclaimer

References

    1. Bajaj A, Driver JA, Schernhamelanomaer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21:697–707. - PubMed
    1. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011;76:2002–2009. - PMC - PubMed
    1. Constantinescu R, Romer M, Kieburtz K. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord. 2007;22:720–722. - PubMed
    1. Schwid SR, Bausch J, Oakes D, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010;25:1801–1808. - PubMed
    1. Elm JJ, Investigators NN-P Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012;27:1513–1521. - PMC - PubMed

Publication types